Clinical trials: Treatment Resistant
Resistant Hypertension
A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety
The goal of this clinical trial is to show the blood pressure lowering effect of aprocitentan, a new drug, when added to other anti-hypertensive drugs of patients with difficult to control (resistant) high blood pressure…
- Trial name
- PRECISION (NCT03541174)
- Testing
- Aprocitentan 12.5 mg, Aprocitentan 25 mg
- Where
- 159 sites in United States, Australia and 18 more
- Volunteers
- 730 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Major Depressive Disorder
Placebo-controlled Trial of 5-hydroxytryptophan and Creatine for SSRI or SNRI Augmentation in Treatment Resistant Depression in Females
The investigators propose to determine if 8 weeks of dietary augmentation with oral 5g creatine monohydrate daily and 100 mg of 5-hydroxytryptophan (5-HTP) twice daily reduces hypoxia-related depressive symptoms measured by the…
- Trial name
- NCT02922725
- Testing
- 5-hydroxytryptophan and Creatine
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Brent Michael Kious, MD, PhD
Stable Angina
Aspirin Resistance and Percutaneous Coronary Intervention (PCI)
The objective of this study is to evaluate if aggressive antiplatelet therapy would reduce ischemic events in aspirin (ASA) resistant patients after percutaneous coronary intervention (PCI).
- Trial name
- RESIST (NCT01103440)
- Testing
- Intravenous Glycoprotein inhibitor + ASA, Clopidogrel, Antiplatelet Therapy (ASA, Clopidogrel)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Ovarian Cancer
Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer
This multi-institutional phase I/II clinical trial will test the tolerability and efficacy of the combination sorafenib and topotecan in patients with recurrent ovarian cancer, which is platinum-resistant (recurrence within 6…
- Trial name
- NCT00526799
- Testing
- Sorafenib, Topotecan
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Daniela Matei, MD
Treatment Resistant Depression
A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression
The purpose of this study is to assess the efficacy and safety of olanzapine and fluoxetine compared to placebo and fluoxetine as treatment for treatment-resistant depression (TRD) in Chinese participants.
- Trial name
- NCT01687478
- Testing
- Olanzapine, Fluoxetine
- Where
- 11 sites in China
- Volunteers
- 176 people
- Sponsor
- Eli Lilly and Company
Gastric Cancer, Adenocarcinoma
Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma
The purpose of this study is to gather information about the use of an investigational drug called Ramucirumab in adenocarcinomas of the stomach or gastroesophageal junction.
- Trial name
- NCT00917384
- Testing
- ramucirumab, Best Supportive Care (BSC)
- Where
- 161 sites in United States, Argentina and 28 more
- Volunteers
- 355 people
- Sponsor
- Eli Lilly and Company
Tuberculosis
To Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-positive Pulmonary MDR-TB.
The purpose of this study is to evaluate the safety, tolerability and effectiveness of TMC207 in combination with an individualized background regimen (BR) of antibacterial drugs as treatment for MDR-TB
- Trial name
- NCT00910871
- Testing
- TMC207, Background Regimen (BR) for MDR-TB
- Where
- 27 sites in China, Estonia and 10 more
- Volunteers
- 241 people
- Sponsor
- Janssen Infectious Diseases BVBA
Metastatic Breast Cancer
Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy
Two thirds or more of breast cancers are dependent on estrogen for growth. We use a number of estrogen-blocking medicines for treatment of metastatic breast cancer.
- Trial name
- NCT00225758
- Testing
- Lapatinib
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Gary Schwartz
Mild Cognitive Impairment
Pioglitazone Or Exercise to Treat Mild Cognitive Impairment (MCI)
The purpose of this study is to investigate novel treatments to delay progression to dementia in patients with mild cognitive impairment (MCI) and metabolic syndrome (MS).
- Trial name
- POEM (NCT00736996)
- Testing
- Pioglitazone, Endurance Exercise Training
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma
AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This trial studies the side effects and best dose of AVB-S6-500 when given together with durvalumab in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that is resistant to platinum therapy or has come…
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT04019288
- Testing
- Batiraxcept, Durvalumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Polycythemia Vera
Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.
This study compared the efficacy and safety of ruxolitinib to Best Available Therapy (BAT) in patients with polycythemia vera (PV) who were hydroxyurea (HU) resistant or intolerant and did not have a palpable spleen.
- Trial name
- RESPONSE-2 (NCT02038036)
- Testing
- Best Available Therapy, Ruxolitinib
- Where
- 48 sites in Australia, Belgium and 10 more
- Volunteers
- 149 people
- Sponsor
- Novartis Pharmaceuticals
Eosinophilia, Hypereosinophilic Syndrome
Steroid Treatment for Hypereosinophilic Syndrome
Background: Hypereosinophilic syndrome (HES) is a disorder in which the body has too many eosinophils (a type of white blood cell). Too many eosinophils in HES can cause damage to the heart, nerves, or skin.
- Conditions
- Eosinophilia, Hypereosinophilic Syndrome, Leukocyte Disorder, Hematologic Diseases
- Trial name
- NCT01524536
- Testing
- prednisone
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Treatment Resistant Major Depressive Disorder
Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD
This is a multi-site, randomized, open-label, effectiveness trial comparing three treatment arms for Major Depressive Disorder (MDD) patients with TRD who are currently on ongoing, stable and adequate antidepressant therapy…
- Trial name
- ASCERTAINTRD (NCT02977299)
- Testing
- Aripiprazole, Repetitive transcranial magnetic stimulation (rTMS), Venlafaxine XR
- Where
- 13 sites in United States, Canada
- Volunteers
- 278 people
- Sponsor
- Massachusetts General Hospital
Prostate Cancer
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
The purpose of this study is to determine what effects (good and bad) cabozantinib has in treatment of patients with metastatic castrate resistant prostate cancer (mCRPC).
- Trial name
- NCT04631744
- Testing
- Cabozantinib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Weill Medical College of Cornell University
Fatty Liver
Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)
The purpose of this study is to find out if Metformin is safe and useful in the treatment of NAFLD.
- Trial name
- NAFLD (NCT00736385)
- Testing
- Glucophage (Metformin)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Duke University
Metastatic Breast Cancer
Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients
This is a single-arm, open-label, phase I/II study. In the phase I, patients with Human Epidermal Growth Factor Receptor 2 (HER2) positive MBC will be treated with paclitaxel, trastuzumab and increasing doses of dasatinib to…
- Trial name
- NCT01306942
- Testing
- Dasatinib, Trastuzumab, Paclitaxel
- Where
- 8 sites in Spain
- Volunteers
- 37 people
- Sponsor
- Spanish Breast Cancer Research Group
Candidemia
An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia
This is a multicenter, open-label, non-comparative, single-arm study to evaluate the efficacy and safety of APX001 for the first-line treatment for candidemia including suspected or confirmed antifungal-resistant candidemia in…
- Trial name
- NCT03604705
- Testing
- APX001
- Where
- 29 sites in United States, Belgium and 3 more
- Volunteers
- 21 people
- Sponsor
- Basilea Pharmaceutica
Acute Coronary Syndrome (ACS), High On-treatment Platelet Reactivity (HTPR)
The Effect of IV Cangrelor and Oral Ticagrelor Study
Major heart attacks are caused by a number of factors, the two major of which are furring up of a coronary artery with atheroma and then sudden clot formation on this area leading to a blockage and interruption of blood flow.
- Conditions
- Acute Coronary Syndrome (ACS), High On-treatment Platelet Reactivity (HTPR), Microvascular Obstruction (MVO), ST-segment Elevation Myocardial Infarction (STEMI)
- Trial name
- NCT02733341
- Testing
- Cangrelor, Ticagrelor
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer
This phase II trial studies how well linsitinib works in treating patients with asymptomatic or mild symptomatic metastatic prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01533246
- Testing
- linsitinib, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Polycythemia Vera
Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.
The purpose of this open-label, single arm, multi-center Expanded Treatment Protocol (ETP) was to provide early access to ruxolitinib and evaluate safety information in patients with polycythemia vera (PV) who were hydroxyurea…
- Trial name
- NCT02292446
- Testing
- Ruxolitinib
- Where
- 65 sites in Austria, Belgium and 10 more
- Volunteers
- 161 people
- Sponsor
- Novartis Pharmaceuticals